“Thanks to the fast and efficient integration of its teams and assets, Inovyn is now a sound and sustainable chlorovinyls player. This allows us to bring forward Solvay's exit and to further focus on its portfolio transformation, while achieving a first step in de-leveraging the balance sheet,” said Jean-Pierre Clamadieu, CEO of Solvay.
Jim Ratcliffe, chairman of Ineos, added, “Ineos is very comfortable with the proposed early acquisition of the full shareholding of the Inovyn joint venture. Chlorovinyls businesses are core to large petrochemicals companies such as ours and through this planned acquisition Inovyn will have an owner with a long term vision that provides stability for its business and employees.”
Closing of the transaction is likely to occur in the second half of 2016, subject to finalising definitive legal agreements and customary regulatory approvals.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)